CSL (OTCMKTS:CSLLY) Shares Gap Up – Here’s What Happened

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $30.92, but opened at $32.1430. CSL shares last traded at $31.30, with a volume of 906 shares changing hands.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a report on Friday, August 7th. Royal Bank Of Canada raised CSL from a “hold” rating to a “moderate buy” rating in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, CSL presently has a consensus rating of “Hold”.

CSL Stock Up 0.8%

The stock’s fifty day moving average is $28.85 and its 200-day moving average is $23.77. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.97 and a current ratio of 2.21.

About CSL

CSL Limited is an Australia-based biopharmaceutical company that develops and manufactures medicines, vaccines and other healthcare products. The company serves patients, healthcare providers and public health systems worldwide through its major businesses, CSL Behring, CSL Seqirus and CSL Vifor.

CSL Behring specializes in plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders, hereditary angioedema and other rare or serious conditions. CSL Seqirus develops and supplies influenza vaccines and other vaccines, while CSL Vifor focuses on treatments for iron deficiency, kidney disease and related conditions.

The company traces its origins to Commonwealth Serum Laboratories, which was established by the Australian government in 1916.